Curcumin Bioavailability in Glioblastoma Patients
Sponsor
Johann Wolfgang Goethe University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT01712542
Collaborator
(none)
15
1
7
2.2
Study Details
Study Description
Brief Summary
Measuring the bioavailability of orally administered curcumin in the tumors of glioblastoma patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
15 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Measurement of Intratumoral Concentration of the Nontoxic Natural Compound Curcumin in Glioblastoma Patients
Study Start Date
:
Oct 1, 2012
Actual Primary Completion Date
:
May 1, 2013
Actual Study Completion Date
:
May 1, 2013
Outcome Measures
Primary Outcome Measures
- Concentration of Curcumin in Glioblastoma [At Tumor resection]
At the time of surgery
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Patients harboring Glioblastoma
-
Patient will undergo surgery
Exclusion Criteria:
-
BMI > 30
-
Liver and Kidney Function so compromised that medication is prescribed
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Neurosurgery, Johann Wolfgang Goethe-University | Frankfurt | Hessen | Germany | 60528 |
Sponsors and Collaborators
- Johann Wolfgang Goethe University Hospital
Investigators
- Principal Investigator: Stephan Duetzmann, Goethe University
Study Documents (Full-Text)
None provided.More Information
Publications
Responsible Party:
Stephan Dützmann,
M.D.,
Johann Wolfgang Goethe University Hospital
ClinicalTrials.gov Identifier:
NCT01712542
Other Study ID Numbers:
- JohannWGUH_Curcumin-01
First Posted:
Oct 23, 2012
Last Update Posted:
Jun 4, 2013
Last Verified:
Jun 1, 2013
Additional relevant MeSH terms: